Ultragenyx Pharmaceutical (RARE) has earned its first FDA approval in gene therapy, landing an accelerated green light for its treatment targeting glycogen storage disease type Ia. The FDA approved pariglasgene brecaparvovec-opnr, previously
Oracle Corporation remains one of the most closely watched names in enterprise software, with its founder Larry Ellison continuing to shape its long-term strategic direction. Founder-led companies have historically demonstrated stronger alignment
More
The FTSE 250 index continues to attract income-focused investors seeking alternatives to low-yielding savings accounts and government bonds in 2026. A dividend yield of around 10% is considered exceptionally high by most
More
Sanofi has returned to France as an Official Health Partner of the Special Olympics Unified Football World Cup, reinforcing its commitment to inclusive sport and public health awareness. The French pharmaceutical giant
More
The Centers for Medicare and Medicaid Services has proposed sweeping new restrictions on how remote monitoring services can be billed under Medicare, targeting outsourced clinical staff arrangements. Published on July 16, the
More
Ben Ginsberg, a longtime Republican elections attorney, has dismissed President Donald Trump’s recent speech about alleged vulnerabilities in US election security. Ginsberg served as national counsel to the presidential campaigns of George
More
UK shares have long been the preferred choice for investors targeting retirement income through a Self-Invested Personal Pension, commonly known as a SIPP. The FTSE 100 is home to many industry-leading blue-chips
More
Legendary investor Warren Buffett has long been regarded as one of the most reliable voices in finance during periods of market turbulence and uncertainty. Buffett’s approach to stock market crashes centres on
More
Alphabet, Microsoft and Amazon will report earnings over the next two weeks as investors demand proof that record AI investment is driving meaningful revenue growth. The three companies have led the AI
More
Johnson and Johnson has now delivered five consecutive quarters of at least 6% revenue growth, demonstrating remarkable resilience in the face of significant headwinds. The pharmaceutical giant’s immunology portfolio absorbed a serious
More
Law firms are falling dangerously behind their clients on artificial intelligence adoption, according to a new report from legal tech vendor BigHand. The findings echo a separate Deloitte Legal survey that revealed
More